Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + metformin
- Development stage
- Preclinical
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cisplatin, gemcitabine, and metformin. Cisplatin and gemcitabine form a standard chemotherapy regimen for various cancers, while metformin is primarily an antidiabetic drug that has shown anticancer properties. Research indicates that metformin enhances the efficacy of gemcitabine and cisplatin by inhibiting cell proliferation and inducing apoptosis through effects on AMPK pathways, cyclin D1, and caspase-3 activation.
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)CASP3 (Caspase-3)DNACCND1 (Cyclin D1)DNA polymerase family
Beyond the preview
Go deeper on cisplatin + gemcitabine + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + metformin.